Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022 at 4:30 p.m. EST
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that It planned to launch its first quarter 2022 financial results after market on Tuesday, May 10, 2022.
Management will hold a conference call to review the company’s performance in the first quarter of 2022 beginning at 4:30 p.m. (ET) the same day. The conference call will be webcast simultaneously. The link to the webcast will be available on the Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations”, then “Events and Publications”, and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (U.S./Canada) or 1-412-317-6061 (International), access code 9027379, approximately ten to five minutes before start time.
Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing blood glucose monitoring products designed to transform the lives of the global diabetes community through differentiated, implantable long-term blood glucose management technology. term. CGM systems from Senseonics, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn on the sensor. Glucose data is automatically sent every 5 minutes to a mobile app on the user’s smartphone.